A strategic framework of natural gum blend matrix tablets in oral sustained delivery of metoprolol succinate – an effort to construct a more patient-centric safe medication: design, development and in-vitro comparative evaluation

Abstract

The purpose of this study is to design and evaluate metoprolol succinate sustained release (SR) matrix tablets using a natural gum blend as the rate-retarder. The development of a tablet matrix utilizing the three natural gums locust bean gum (LBG), xanthan gum (XG), and guar gum (GG) was done to facilitate metoprolol succinate release over a 24-hour period and help in once-daily dose, minimizing nocturnal episodes in anti-hypertensive patients. Attempts were made to generate a synergistic effect by combining two regularly used natural gums, XG and GG, with LBG, which functioned as the principal release-retardant. Because metoprolol succinate is one of the most commonly used antihypertensive drugs, we focused on developing a formulation using natural polymers to save patients from ingesting significant amounts of synthetic polymers on a regular basis. Various polymer blend ratios were used to determine the best approach to formulate the tablet. The same polymer mix was utilized as the binding agent in the wet granulation process for developing tablets. The formulations were characterized using weight, thickness, hardness, content homogeneity, in-vitro drug release, erosion, and water uptake. Stability tests and further drug-excipient compatibility testing were carried out. An XG:LBG:GG ratio of 1:2:1 was discovered to yield the best results, exceeding commercial formulations. A relationship between gum concentration and the release rate retarding impact was additionally established. The gum concentration of 3.33% demonstrated the best sustained release effects. As a result, it can be stated that the manufactured SR metoprolol succinate tablets may be one of the best preparations for hypertensive patients because it not only serves therapeutic purposes but also values the patients' concern for minimizing side effects in the long run use of the drug.